SNY vs. REGN
SNY (Sanofi) and REGN (Regeneron Pharmaceuticals, Inc.) are both stocks. Both are in the Healthcare sector — SNY in Drug Manufacturers - General, REGN in Biotechnology. Over the past 10 years, SNY returned 4.83%/yr vs 6.24%/yr for REGN. Their 0.30 correlation means their historical movements had little consistent relationship.
Performance
SNY vs. REGN - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, SNY achieves a -6.82% return, which is significantly lower than REGN's -0.16% return. Over the past 10 years, SNY has underperformed REGN with an annualized return of 4.83%, while REGN has yielded a comparatively higher 6.24% annualized return.
SNY
- 1D
- 0.23%
- 1M
- 0.40%
- 6M
- -6.09%
- YTD
- -6.82%
- 1Y
- -5.61%
- 3Y*
- -1.64%
- 5Y*
- 0.85%
- 10Y*
- 4.83%
- ALL TIME*
- 5.27%
REGN
- 1D
- 1.04%
- 1M
- 18.28%
- 6M
- -0.57%
- YTD
- -0.16%
- 1Y
- 35.60%
- 3Y*
- 0.37%
- 5Y*
- 4.87%
- 10Y*
- 6.24%
- ALL TIME*
- 10.60%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
| $660.53M | $541.93M | $661.12M | |
SNY Sanofi | $151.24M | $142.28M | $147.68M |
SNY vs. REGN - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
SNY Sanofi | -6.82% | 4.93% | 1.09% | 6.55% | 0.57% | 7.00% | 0.39% | 20.47% | 6.06% | 9.96% |
REGN Regeneron Pharmaceuticals, Inc. | -0.16% | 8.96% | -18.90% | 21.73% | 14.25% | 30.72% | 28.66% | 0.53% | -0.65% | 2.42% |
Correlation
The correlation between SNY and REGN is 0.38, which is low. Their historical price movements had little consistent relationship.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | 0.38 |
Correlation (3Y) Balances recent behavior with more history. | 0.37 |
Correlation (5Y) Shows whether the relationship held over a longer period. | 0.36 |
Correlation (10Y) Provides a long-term view across more market conditions. | 0.35 |
Correlation (All Time) Calculated using the full available price history since Jul 1, 2002 | 0.30 |
Fundamentals
SNY:
$102.72B
REGN:
$79.18B
SNY:
€1.63
REGN:
$40.34
SNY:
22.75
REGN:
19.05
SNY:
1.84
REGN:
5.31
SNY:
1.28
REGN:
2.11
SNY:
€48.92B
REGN:
$15.53B
SNY:
€35.72B
REGN:
$13.69B
SNY:
€12.41B
REGN:
$5.38B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
SNY vs. REGN — Risk / Return Rank
SNY
REGN
SNY vs. REGN - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Sanofi (SNY) and Regeneron Pharmaceuticals, Inc. (REGN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| SNY | REGN | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.28 | ||
| Sortino ratioReturn per unit of downside risk | -1.80 | ||
| Omega ratioGain probability vs. loss probability | 0.98 | 1.21 | -0.23 |
| Calmar ratioReturn relative to maximum drawdown | -0.34 | 1.38 | -1.72 |
| Martin ratioReturn relative to average drawdown | -0.58 | 3.27 | -3.85 |
Loading charts...
Drawdowns
SNY vs. REGN - Drawdown Comparison
The maximum SNY drawdown since its inception was -46.46%, smaller than the maximum REGN drawdown of -91.81%. Use the drawdown chart below to compare losses from any high point for SNY and REGN.
Loading charts...
Drawdown Indicators
| SNY | REGN | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -46.46% | -91.81% | +45.35% |
Max Drawdown (1Y)Largest decline over 1 year | -16.70% | -25.85% | +9.15% |
Max Drawdown (3Y)Largest decline over 3 years | -23.37% | -59.69% | +36.32% |
Max Drawdown (5Y)Largest decline over 5 years | -33.52% | -59.69% | +26.17% |
Max Drawdown (10Y)Largest decline over 10 years | -33.52% | -59.69% | +26.17% |
Current DrawdownCurrent decline from peak | -20.64% | -35.52% | +14.88% |
Average DrawdownAverage peak-to-trough decline | -12.24% | -42.46% | +30.22% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 9.70% | 10.92% | -1.22% |
Volatility
SNY vs. REGN - Volatility Comparison
The current volatility for Sanofi (SNY) is 7.74%, while Regeneron Pharmaceuticals, Inc. (REGN) has a volatility of 9.51%. This indicates that SNY experiences smaller price fluctuations and is considered to be less risky than REGN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| SNY | REGN | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 7.74% | 9.51% | -1.77% |
Volatility (6M)Calculated over the trailing 6-month period | 17.48% | 23.33% | -5.85% |
Volatility (1Y)Calculated over the trailing 1-year period | 25.46% | 33.65% | -8.19% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 25.14% | 31.06% | -5.92% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 23.47% | 32.16% | -8.69% |
Dividends
SNY vs. REGN - Dividend Comparison
SNY's dividend yield for the trailing twelve months is around 5.66%, more than REGN's 0.47% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
REGN Regeneron Pharmaceuticals, Inc. | 0.47% | 0.46% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
SNY Sanofi | 5.66% | 4.56% | 4.22% | 3.83% | 4.32% | 3.80% | 3.61% | 3.47% | 4.29% | 3.82% | 4.11% | 3.77% |
Financials
SNY vs. REGN - Financials Comparison
This section allows you to compare key financial metrics between Sanofi and Regeneron Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
SNY vs. REGN - Profitability Comparison
SNY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Sanofi reported a gross profit of 9.28B and revenue of 12.30B. Therefore, the gross margin over that period was 75.5%.
REGN - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Regeneron Pharmaceuticals, Inc. reported a gross profit of 4.22B and revenue of 4.29B. Therefore, the gross margin over that period was 98.3%.
SNY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Sanofi reported an operating income of 2.38B and revenue of 12.30B, resulting in an operating margin of 19.4%.
REGN - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Regeneron Pharmaceuticals, Inc. reported an operating income of 1.29B and revenue of 4.29B, resulting in an operating margin of 30.2%.
SNY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Sanofi reported a net income of 343.00M and revenue of 12.30B, resulting in a net margin of 2.8%.
REGN - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Regeneron Pharmaceuticals, Inc. reported a net income of 1.30B and revenue of 4.29B, resulting in a net margin of 30.2%.
Frequently Asked Questions
SNY and REGN have a correlation of 0.38, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
REGN has higher volatility (9.51%) compared to SNY (7.74%). In terms of maximum drawdown, SNY dropped -46.46% vs REGN's -91.81%.
REGN currently has the higher Sharpe Ratio (1.06 vs -0.22), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for SNY and REGN
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer